Search Technologies

The National Cancer Institute seeks partners interested in licensing or co-development of assays for determining the levels of gamma-H2AX/H2AX to measure and quantify DNA damage.

The National Cancer Institute (NCI) seeks research, co-development, or licensing partners for software that uses computational approaches in cancer diagnosis. NCI researchers have recently developed a computational approach for detecting, quantifying, and mapping Mitotic Hotspots in whole slide images of tumor tissue. This technology has demonstrated high reproducibility that is unaffected by diagnostic skill or fatigue, allowing standardization of tumor cell proliferation assessment across institutions.

The National Cancer Institute (NCI) seeks licensees for an automated digital pathology device which integrates tissue sectioning, staining, and image acquisition. The device is compatible with high-throughput data analyses.

The National Cancer Institute (NCI) seeks licensing of Bac-2-the-Future, an improved system for the production of recombinant baculovirus.

Chimeric Antigen Receptors (CARs) are engineered proteins that can be used in a therapeutic capacity when expressed by an immune cell (e.g., a T cell). Specifically, CARs comprise a targeting domain (such as an antibody or binding fragment thereof) as well as domains that activate immune cells. By selecting a targeting domain that binds to a protein that is selectively expressed on a cancer cell, it is possible to target immune cells to the cancer cells. Upon binding to the target cell, the immune cells are activated, leading to the destruction of the cancer cell. This therapeutic approach holds great promise, as evidenced by the recent FDA-approval of CAR-T cell therapies, KYMRIAH and YESCARTA, both of which target CD19.

Researchers at the National Cancer Institute (NCI) have developed a bioluminescent MB49-luciferase bladder cancer cell line that can be used in preclinical studies to evaluate anti-cancer agents in bladder cancer. NCI seeks parties to non-exclusively license this research material.

The National Institute of Health, National Cancer Institute is seeking parties interested in licensing a marker for predicting taxane chemotherapy outcome.

The National Cancer Institute (NCI) seeks co-development or licensees for Dual-Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors

Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Stimulation of T cells with the Brachyury peptide promote a robust immune response and lead to targeted lysis of invasive tumor cells. NCI seeks licensing or co-development of this invention.